03692 Overview

Stock Performance: Several pharmaceutical stocks showed mixed performance, with HENGRUI PHARMA and HANSOH PHARMA experiencing gains, while SINO BIOPHARM saw a decline.

Short Selling Data: Short selling activity varied across companies, with SINO BIOPHARM having the highest short selling amount at $180.02M and a ratio of 40.682%.

Target Prices: Analysts have set target prices for various stocks, with HENGRUI PHARMA and HANSOH PHARMA rated as "Buy" with target prices of HK$98.3 and HK$51.5, respectively.

Market Sentiment: CSPC PHARMA received a "Neutral" rating, indicating a more cautious outlook compared to the "Buy" ratings for other companies listed.

Company Performance: HANSOH PHARMA expects a 10% growth in both revenue and earnings for FY26, with a projected 27% YoY revenue increase in 2H25 to RMB7.3 billion, driven by a 17% growth in drug sales.

Analyst Forecasts: Nomura has raised its FY25 revenue and earnings forecasts for HANSOH PHARMA by 1% and 4.7% respectively, adjusting for higher collaboration revenue, and has increased the target price from HKD35.5 to HKD37.87 while maintaining a Neutral rating.

Chinese Internet Healthcare Sector Growth: The sector is evolving with increased AI innovation from tech giants and support from national policies, such as Beijing's online consultation pilot program, despite profitability challenges.

Stock Recommendations: UOB Kay Hian maintains a positive outlook on companies like ALI HEALTH and PA GOODDOCTOR, projecting significant revenue growth driven by AI and synergies with major partners.

Top Picks in Healthcare: UOB Kay Hian's top stock picks include BEONE MEDICINES, INNOVENT BIO, and HANSOH PHARMA, highlighting their potential for growth in the Chinese healthcare market.

Investment Ratings: Various companies in the sector have received investment ratings, with several being rated as "Buy," indicating strong confidence in their future performance.

Healthcare Sector Outlook: Goldman Sachs predicts that the strong trend in China's healthcare sector will continue, with stock trading increasingly focused on companies' execution capabilities and R&D pipelines rather than just licensing expectations.

CDMO Companies Favorable: The broker is optimistic about CDMO companies due to their growth potential and reasonable valuations, upgrading WUXI APPTEC and WUXI XDC to Buy.

Selective Biotech and Pharma Strategy: Goldman Sachs favors biotech and pharmaceutical companies with promising data releases and transaction expectations, highlighting SKB BIO-B, HENLIUS, and HANSOH PHARMA as favorable investments.

Cautious on Medical Services: The broker maintains a neutral stance on the medical devices sector and is cautious about medical services due to cost control measures and weak consumption, downgrading HYGEIA HEALTH and JXR to Neutral/Sell.

Stock Performance: Hansoh Pharma's stock opened down 1.04% and traded at HKD38.26, reflecting a decline of 4.92% with significant short selling activity amounting to $44.60 million.

Convertible Bonds Issuance: The company announced a proposed issuance of HKD4.68 billion in zero-coupon convertible bonds due in 2033, with a conversion price set at HKD57.39, representing a 42.62% premium over the previous day's closing price.

Market Overview: The HSI opened 0.4% higher at 26,863, with the HSCEI and HSTECH also showing slight gains at 9,173 and 5,734, respectively.

Tech Stock Movements: BABA-W launched a new reasoning model and opened up 1%, while other major tech stocks like TENCENT and KUAISHOU-W saw minor increases, whereas JD-SW and BIDU-SW experienced slight declines.

Automotive Sector Updates: BYD and NIO both saw a 1% increase, while XIAOMI-W also grew slightly, indicating positive movement in the automotive market.

Significant Corporate Actions: ANTA SPORTS became Puma's largest shareholder with a 29% stake acquisition, while ZIJIN GOLD INTL surged 12.165% after announcing plans to take over Allied Gold for RMB28 billion.